NASDAQ: RETA

US-based Biogen Inc., (NASDAQ: BIIB) has announced that it has reached an agreement to fully acquire compatriot firm Reata Pharmaceuticals Inc., (NASDAQ: RETA) in a cash deal valued at USD 172.50 per share, totaling USD 7.3 billion. The acquisition is anticipated to be completed in the fourth quarter of 2023.…